Itonis Pharmaceuticals Announces Completion of Stability Test for Emesyl® and Delivery Date of Emesyl® with New Packaging D...

 

Itonis Pharmaceuticals Announces Completion of Stability Test for Emesyl® and Delivery Date of Emesyl® with New Packaging Design

 

LAGUNA HILLS, CA - December 18, 2014 - InvestorsHub NewsWire - Itonis, Inc. (OTC PINKSHEETS: ITNS)

 

Itonis is pleased to announce that it has received confirmation from its manufacturer, Oasis Health Products, that its Emesyl® nausea relief product has passed its Stability Test to enable the company to market Emesyl® with a 2-year expiration date.

 

Oasis Health Products has also confirmed that Itonis will receive delivery by December 19, 2014 of Emesyl® with its new packaging design.  

 

"We are pleased to see the successful completion of the 90-day stability test which will enable the Company to package and sell Emesyl® with a 2-year expiration,” said Mark Cheung, CEO of Itonis, Inc.  "We appreciate our shareholders' support and patience, and are eager to begin the selling of Emesyl® to generate revenues for the Company."

 

The Company also looks forward to delivery of the MyECheck, Inc. point-of-sale app in early 2015.

 

About Itonis Pharmaceuticals

 

Itonis Pharmaceuticals, a division of Itonis, Inc., is headed by Charles Hensley, Ph.D., and its mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations.  He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States.  Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.

About Itonis, Inc.

Located in Laguna Hills, California, and founded in 2005, Itonis Inc. has focused on transitioning itself in the past year from acquiring high growth, market niche entrepreneurial companies, to a market leader focused on the distribution of innovative products to the medical and pharmaceutical industry. Please visit www.itonisholdings.com.

 

About Emesyl®

www.itonisholdings.com/emesyl

About Oasis

www.oasishp.com/home/about/

 

Safe Harbor:

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

Contact:

Itonis, Inc.

[e-mail]